Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Business Wire•24/10/2026•11:18 ET
6
Key Highlights
- ➤25vPnC elicited robust immune responses against all 25 serotypes in infants
- ➤25vPnC safety and tolerability were comparable to four doses of PREVNAR 20
- ➤Serotype 3 GMCs were 8.8-fold higher after Dose 3 versus PREVNAR 20
- ➤Serotype 3 GMCs were approximately 15-fold higher after Dose 4 versus PREVNAR 20
- ➤Phase 3 pediatric program began with up to 6,830 randomized participants
Expert Statements
Annaliesa Anderson, Senior Vice President and Chief Vaccines Officer, Pfizer
“These encouraging data build on more than 25 years of progress in protecting children from serious pneumococcal disease with PREVNAR vaccines. By expanding serotype coverage and applying next-generation technology to the historically challenging serotype 3, this candidate aims to extend the substantial reductions in disease that existing vaccines have achieved. If successful, it could help provide children with the broadest protection against invasive pneumococcal disease to date.”
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20(® )on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal disease (IPD) for pediatric population in the U.S.
Get started
Create a free account to read the full story.